Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.
Phase II trial of low-dose oral etoposide in AIDS-related Kaposi's sarcoma (KS) (Meeting abstract).
Proc Annu Meet Am Soc Clin Oncol; 12:A19 1993. Unique Identifier : AIDSLINE ICDB/93694419 Sander E; Zampese M; Prolla G; Marques A; Jung F; Venegas LF; Sprinz E; Kronfeld M; Kalakun L; Mans DA; et al; South-American Office for Anticancer Drug Development, Hosp. de; Clinicas de Porto Alegre, Brazil
Abstract:
Etoposide is a topoisomerase II inhibitor whose antitumor activity in preclinical models appears to be schedule-dependent. Notably prolonged drug administration was shown to improve treatment results in patients (pts) with tumors such as small cell lung cancer. In this Phase II trial, oral etoposide was given at the dose of 25 mg/m2 bid for 7 days every 2 wk. Up to now, 9 homosexual men with progressing KS were accrued. Median age was 36 yr (range 25-45). Three pts were Stage IIIA, 3 pts were Stage IVA, 1 pt was IIIB and 2 pts were IVB according to NYU criteria. All pts received AZT + cotrimoxazole during all courses. Three pts had received previous chemotherapy (CT; doxorubicin+vincristine+bleomycin) and 1 pt received interferon alfa 2a. Median performance status (WHO) was 1 (range 0-2). There were no opportunistic infections other than mucocutaneous candidiasis. A median of 5 courses per pt (range 1-15) was given. Overall response (CR+PR) was 44% (4/9 pts). One pt achieved CR (11%). Minor responses (MR) were seen in 3 pts, all previously exposed to CT. The median duration of responses was 12 wk (range 4-30). Five pts developed opportunistic infections (Pneumocystis carinii in 3 pts, tuberculosis and cryptococcosis in 2 pts, respectively). Major toxicities were leukopenia (WHO grade I and II in 45/58 courses and grade III in 13/58 courses), alopecia (WHO grade I in 2 pts and grade II in 3 pts) and nausea (WHO grade I in 3 pts). No pt was admitted to the hospital, except for the treatment of opportunistic infections. Preliminary results suggest that oral etoposide is an active agent in AIDS-related KS, suitable for outpatient administration and having manageable toxicity. The trial is still open for accrual.
Keywords: Acquired Immunodeficiency Syndrome/*DRUG THERAPY Administration, Oral Adult Dose-Response Relationship, Drug Etoposide/*ADMINISTRATION & DOSAGE/ADVERSE EFFECTS Human Male Sarcoma, Kaposi's/*DRUG THERAPY ABSTRACT 931230
M93C0811
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.
